London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fourth patent by the US Patent and Trademark Office (USPTO). This is COMPASS’s first patent with claims covering its Form A hydrate psilocybin.


Previous articleFirst Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial
Next articleNuminus Advances Phase 1 Trial on Proprietary Psilocybin Product